166 related articles for article (PubMed ID: 30962674)
1. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis.
Pepose JS; Narvekar A; Liu W; Haque R
Clin Ophthalmol; 2019; 13():535-544. PubMed ID: 30962674
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2018 Oct; 194():7-15. PubMed ID: 29787732
[TBL] [Abstract][Full Text] [Related]
3. A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
Am J Ophthalmol; 2020 Jul; 215():56-65. PubMed ID: 32222367
[TBL] [Abstract][Full Text] [Related]
4. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.
Pelletier JS; Stewart K; Trattler W; Ritterband DC; Braverman S; Samson CM; Liang B; Capriotti JA
Adv Ther; 2009 Aug; 26(8):776-83. PubMed ID: 19756415
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
6. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Single Administration of 5% Povidone-Iodine in the Treatment of Adenoviral Conjunctivitis.
Than T; Morettin CE; Harthan JS; Hartwick ATE; Huecker JB; Johnson SD; Migneco MK; Shorter E; Whiteside M; Olson CK; Alferez CS; van Zyl T; Rodic-Polic B; Storch GA; Gordon MO
Am J Ophthalmol; 2021 Nov; 231():28-38. PubMed ID: 34102153
[TBL] [Abstract][Full Text] [Related]
8. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.
Shorter E; Whiteside M; Harthan J; Margolis MS; Hartwick AT; Johnson S; Migneco M; Morettin C; Olson CK; Huecker J; Than T; Gordon MO
Ocul Surf; 2019 Oct; 17(4):828-832. PubMed ID: 31401340
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial.
Pinto RD; Lira RP; Abe RY; Zacchia RS; Felix JP; Pereira AV; Arieta CE; de Castro RS; Bonon SH
Curr Eye Res; 2015 Sep; 40(9):870-7. PubMed ID: 25310347
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Adenoviral Titers with Severity of Adenoviral Conjunctivitis and Time to Viral Clearance for 21 Days.
Morettin CE; Harthan JS; Huecker JB; Perera CD; Than T; Whiteside M; Johnson SD; Shorter E; Migneco MK; Olson CK; Alferez CS; Camp D; Hartwick ATE; Gordon MO
Optom Vis Sci; 2023 Mar; 100(3):187-193. PubMed ID: 36749104
[TBL] [Abstract][Full Text] [Related]
13. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Comstock TL; Paterno MR; Decory HH; Usner DW
Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472
[TBL] [Abstract][Full Text] [Related]
16. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL
Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612
[TBL] [Abstract][Full Text] [Related]
17. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
19. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
Malhotra R; Ackerman S; Gearinger LS; Morris TW; Allaire C
Drugs R D; 2013 Dec; 13(4):243-52. PubMed ID: 24142473
[TBL] [Abstract][Full Text] [Related]
20. The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial.
Cagini C; Mariniello M; Messina M; Muzi A; Balducci C; Moretti A; Levorato L; Mencacci A
Int Ophthalmol; 2020 Dec; 40(12):3209-3215. PubMed ID: 32696102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
